StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$21.89−0.22 (-1.00%)

Close on Nov 18, 2026Market cap $3.69BP/E –Yield –

Tango Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Tango Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$143.90M. For fiscal 2025 it was -$138.89M. The highest annual figure on record is $70.07M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$138.89M–
FY2024Dec 31, 2024-$131.50M–
FY2023Dec 31, 2023-$117.98M–
FY2022Dec 31, 2022-$109.08M–
FY2021Dec 31, 2021-$59.53M-184.9%
FY2020Dec 31, 2020$70.07M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$38.87M–
Q1 FY2026Mar 31, 2026-$44.36M–
Q4 FY2025Dec 31, 2025-$29.72M–
Q3 FY2025Sep 30, 2025-$30.95M–
Q2 FY2025Jun 30, 2025-$36.52M–
Q1 FY2025Mar 31, 2025-$41.70M–
Q4 FY2024Dec 31, 2024-$36.65M–
Q3 FY2024Sep 30, 2024-$33.39M–
Q2 FY2024Jun 30, 2024-$23.61M–
Q1 FY2024Mar 31, 2024-$37.86M–
Q4 FY2023Dec 31, 2023-$27.47M–
Q3 FY2023Sep 30, 2023-$31.14M–
Q2 FY2023Jun 30, 2023-$24.47M–
Q1 FY2023Mar 31, 2023-$34.91M–
Q4 FY2022Dec 31, 2022-$28.27M–
Q3 FY2022Sep 30, 2022-$19.61M–
Q2 FY2022Jun 30, 2022-$31.54M–
Q1 FY2022Mar 31, 2022-$29.67M–
Q4 FY2021Dec 31, 2021-$16.90M–
Q3 FY2021Sep 30, 2021-$21.49M–
Q2 FY2021Jun 30, 2021-$7.52M–
Q1 FY2021Mar 31, 2021-$13.61M–
Q4 FY2020Dec 31, 2020-$18.06M–

More Tango Therapeutics figures

See a number that looks wrong?